Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureSarena Yang, Justin Hyun, Mandar A. Aras
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
10.1016/j.jacc.2022.11.022 · 2023
Redefining the Epidemiology of Cardiac Amyloidosis. A Systematic Review and Meta-Analysis of Screening Studies
10.1002/ejhf.2532 · 2022
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis
2020
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
10.1093/eurheartj/ehx350 · 2017
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
10.1016/0140-6736(93)93127-m · 1993
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
10.1056/nejmoa1805689 · 2018
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review
10.1016/j.jacc.2019.04.003 · 2019
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
10.1126/science.1079589 · 2003
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
10.1016/j.jacc.2018.07.092 · 2018
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
10.1007/s40120-016-0040-x · 2016
Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy
10.1016/0960-8966(96)88826-2 · 1996
Transmission of Systemic Transthyretin Amyloidosis by Means of Domino Liver Transplantation
10.1056/nejm200506023522219 · 2005
Trans-Suppression of Misfolding in an Amyloid Disease
10.1126/science.1062245 · 2001
Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story
10.2147/dddt.s289772 · 2021
Tafamidis for transthyretin familial amyloid polyneuropathy
10.1212/wnl.0b013e3182661eb1 · 2012
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis
10.1007/s12265-013-9512-x · 2013
Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
10.1007/s12265-015-9613-9 · 2015
Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes
10.1161/circheartfailure.113.000890 · 2015
Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage
10.1002/ejhf.3696 · 2025
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association
10.1161/cir.0000000000000792 · 2020
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
10.1016/j.jacc.2025.09.004 · 2026
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
10.1161/circulationaha.119.045093 · 2020
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
10.1002/ejhf.2027 · 2021
Unresolved referenced work
Kept as external metadata until matched
Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone
10.1016/j.jaccas.2020.09.037 · 2020
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
10.1016/j.jacc.2024.11.042 · 2025
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
10.1056/nejmoa1716153 · 2018
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
10.1001/jama.2023.18688 · 2023
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
10.1056/nejmoa2107454 · 2021
Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy
10.1007/s40119-025-00424-6 · 2025
Combination Therapy Versus Monotherapy In Hereditary Transthyretin Amyloidosis
10.1016/j.cardfail.2024.10.407 · 2025
No additional external references are available.